Pharmacy compounding primer for physicians: Prescriber beware

Drugs

Volumn 72, Issue 16, 2012, Pages 2043-2050

  Sellers, Sarah ^a   Utian, Wulf H ^b  

^a Q Vigilance   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Branded drugs; Generic drugs; Legislation; Pharmaceutical services; Regulatory process

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; GENERIC DRUG; HYDROXYPROGESTERONE; PROGESTERONE; TETRADECYL SULFATE SODIUM;

BLOODSTREAM INFECTION; DRUG APPROVAL; DRUG CONTROL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENDOPHTHALMITIS; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICOLEGAL ASPECT; MORBIDITY; MORTALITY; PHARMACIST; PHYSICIAN; PRESCRIPTION; PSEUDOMONAS FLUORESCENS; REVIEW; STREPTOCOCCUS INFECTION; TABLET FORMULATION;

DRUG COMPOUNDING; HUMANS; NONPRESCRIPTION DRUGS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84867729655     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11640850-000000000-00000     Document Type: Review

References (34)

1. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Guidance for Industry: providing clinical evidence of effectiveness for human drug and biological products. Rockville (MD): CDER, 1998 May [online]. Available from URL: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM078749.pdf [Accessed 2012 Sep 27]
2. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Office of Regulatory Affairs (ORA). Guidance for industry: CGMP for phase 1 investigational Drugs. Rockville (MD): US FDA, 2008 Jul [online]. Available from URL: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070273.pdf [Accessed 2012 Sep 27]
3. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Center for Veterinary Medicine (CVM). Office ofRegulatory Affairs (ORA). Guidance for Industry: quality systems approach to pharmaceutical CGMP regulations. Rockville (MD): US FDA, 2006 Sep [online]. Available fromURL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070337.pdf [Accessed 2012 Sep 27]
4. US Department of Health and Human Services. US Food and Drug Administration. The special risks of pharmacy compounding [online]. Available from URL: http://www. fda.gov/ForConsumers/ConsumerUpdates/ucm107836.htm [Accessed 2012 Sep 27]
5. Nahata MC, Allen Jr LV. Extemporaneous drug formulations. Clin Ther 2008; 30 (11): 2112-9
6. Glass BD, Haywood A. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products. J Pharm Pharm Sci 2006; 9 (3): 398-426
7. Galston SK. Federal and state role in pharmacy compounding and reconstitution: exploring the right mix to protect patients. Hearing on Oversight Before the Senate Committee on Health, Education, Labor, and Pensions, 108th Cong. 2003 Oct 23 [online]. Available from URL: http://www.fda.gov/ NewsEvents/Testimony/ucm115010.htm [Accessed 2012 Sep 27]
8. US Department of Health and Human Services. US Food and Drug Administration. Questions and answers on updated FDA statement on compounded versions of hydroxyprogesterone caproate (the active ingredient in Makena). 2012 Jun 29 [online]. Available from URL: http://www.fda. gov/newsevents/newsroom/ pressannouncements/ucm310215. htm [Accessed 2012 Sep 27]
9. US Food and Drug Administration. Importation of active pharmaceutical ingredients (APIs) requirements CPG 460.200 pharmacy compounding compliance policy guides manual (Tab M). 2002 May [online]. Available from URL: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM118050.pdf [Accessed 2012 Sep 27]
10. Gozen EL. Current topics in pharmacy compounding. 2011 May 24 [online]. Available from URL: http://www.nabp. net/meetings/assets/FDA%20Update.pdf [Accessed 2012 Sep 27]
11. United States Supreme Court: Western States Medical Center et al. Petition for a writ of certiorari. 2001 [online]. Available from URL: http://www.justice.gov/osg/briefs/2001/2pet/7pet/2001-0344.pet.aa.pdf [Accessed 2012 Sep 27]
12. Sellers SL. Federal and State Role in Pharmacy Compounding and Reconstitution: Exploring the Right Mix to Protect Patients: Hearing on Oversight Before the Senate Committee on Health, Education, Labor, and Pensions, 108th Cong. 2003 Oct 23 [online]. Available from URL: http://www.pharmwatch. org/comp/sellers.shtml [Accessed 2012 Sep 27]
13. Boodoo JM. Compounding problems and compounding confusion: federal regulation of compounded drug products and the FDAMA circuit split. Am J Law Med 2010; 36 (1): 220-47
14. Pseudomonas bloodstream infections associated with a heparin/saline flush: Missouri, New York, Texas, and Michigan, 2004-2005.MMWR Morb Mortal Wkly Rep 2005; 54 (11): 269-72
15. Whelan GJ, Spahn JD, Brown EE, et al. Subpotentcy of a compounded budesonide for nebulization product in a patient with poorly controlled asthma. J Allergy Clin Immunol 2006; 117: S12
16. US Department of Health and Human Services. US FDA. FDA alerts health care professionals of infection risk from repackaged avastin intravitreal injections. 2011 Aug 30 [online]. Available from URL: http://www.fda.gov/Drugs/ DrugSafety/ucm270296.htm [Accessed 2012 Sep 27]
17. Chollet JL, Jozwiakowski MJ. Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection. Drug Dev Ind Pharm 2012; 38 (5): 540-9
18. Heinrich J. United States General Accounting office. Testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate. Prescription drugs: state and federal oversight of drug compounding by pharmacies. 2003 Oct 23 [online]. Available from URL: http://gao.gov/assets/120/110456.pdf [Accessed 2012 Sep 27]
19. US Department of Health and Human Services. US FDA. 2006 limited FDA survey of compounded drug products. 2010 Mar 22 [online]. Available from URL: http://www.fda. gov/Drugs/GuidanceComplianceRegulatoryInformation/ PharmacyCompounding/ucm204237.htm [Accessed 2012 Sep 27]
20. Crill CM, Hak EB, Robinson LA, et al. Evaluation of microbial contamination associated with different preparation methods for neonatal intravenous fat emulsion infusion. Am J Health Syst Pharm 2010; 67 (11): 914-8
21. Green DM, Jones AC, Brain KR. Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. J Clin Pharm Ther 2012; 37 (1): 53-7
22. Ybarra JV, Rose WE, Curtis CS, et al. Sterility of pediatric lipid emulsions repackaged by an automated compounding device. JPEN J Parenter Enteral Nutr 2011; 35 (3): 391-4
23. Missouri Division of Professional Registration. Board of Pharmacy. Pharmacy compounding report FY 2006-2009 [online]. Available from URL: http://pr.mo.gov/pharma cists-compounding.asp [Accessed 2012 Sep 27]
24. Kato Z, Nakamura M, Yamagishi Y, et al. Pediatric thioridazine poisoning as a result of a pharmacy compounding error. Pediatric reports 2009 Jun 8; 1 (1): e9
25. Missouri Department of Economic Development. Missouri Board of Pharmacy takes action against Kansas City company [media release]. 2003 Mar 10 [online]. Available from URL: http://pr.mo.gov/boards/pharmacy/press/2003-10-03.pdf [Accessed 2012 Sep 27]
26. Stagg-Elliott V. Drug diluting in Kansas City: a pharmacist's crime shakes a community. amednews.com 2002 May 20 [online]. Available from URL: http://www.amaassn. org/amednews/2002/05/20/hll10520.htm [Accessed 2012 Sep 27]
27. Goldman MP. Sodium tetradecyl sulfate for sclerotherapy treatment of veins: is compounding pharmacy solution safe? Dermatol Surg 2004; 30 (12 Pt 1): 1454-6
28. Mahaguna V, McDermott JM, Zhang F, et al. Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel. Drug Dev Ind Pharm 2004; 30 (10): 1069-78
29. Ha K, Krutoholow E. Acorda Therapeutics' fampridine-SR likely to receive FDA approval with REMS/black box label. Financial Times 2009 Oct 2 [online]. Available from URL: http://www.ft.com/intl/cms/s/2/b7b50454-af64-11de-ba1c- 00144feabdc0.html#axzz215F9iIhd [Accessed 2012 Sep 27]
30. US Department of Health and Human Services. US FDA. Bio-identicals: sorting myths from facts. 2008 Apr 8 [online]. Available from URL: http://www.fda.gov/down loads/ForConsumers/ConsumerUpdates/ucm049312.pdf [Accessed 2012 Sep 27]
31. Baker DA, Gass MLS, Utian WH. The truth about bioidentical hormone therapy. The American College of Obstetricians and Gynecologists, Continuing Medical Education 2012 Feb 1; 37 (8) [online]. Available from URL: http://www.acogupdate.com/?gp-page=p-onecourse&gp-skey=311 [Accessed 2012 Feb 27]
32. US Department of Health and Human Services. US FDA. FDA statement on Makena [media release]. 2011 Mar 30 [online]. Available from URL: http://www.fda.gov/news Events/Newsroom/PressAnnouncements/ucm249025.htm [Accessed 2012 Sep 27]
33. Mckenna KJ. Compounded sclerosing agents: risks and consequences. Vein Magazine 2008; 1 (2) [online]. Available from URL: http://www.veindirectory.org/ magazine/article/compounded-sclerosing-agents-risks-and-consequences [Accessed 2012 Sep 27]
34. Krochmal L. Considerations before choosing (extemporaneously) compounded products. Dermatol Ther 2009; 22 (3): 225-8